14394-56-0

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyrimidinamine, 6-chloro-5-methyl(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be incorporated into the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Pyrimidinamine, 6-chloro-5-methyl(9CI) serves as a crucial building block for the creation of agrochemicals. Its application in this field aids in the development of new pesticides and other agricultural products, enhancing crop protection and yield.
Used in Organic Chemistry Research:
4-Pyrimidinamine, 6-chloro-5-methyl(9CI) is utilized as a research compound in organic chemistry. Its properties and reactivity make it a valuable tool for studying various chemical reactions and mechanisms, furthering the understanding of organic chemistry principles.
Used in Production of Other Organic Compounds:
As an intermediate, 4-Pyrimidinamine, 6-chloro-5-methyl(9CI) is involved in the production of other organic compounds. Its versatility in chemical reactions enables the synthesis of a wide range of organic molecules, expanding the scope of organic chemistry applications.

InChI:InChI=1/C5H6ClN3/c1-3-4(6)8-2-9-5(3)7/h2H,1H3,(H2,7,8,9)

Upstream product

• 4316-97-6 4,6-dichloro-5-methylpyrimidine 
• 63447-38-1 5-methyl-1H-pyrimidine-4,6-dione 

Downstream Products

• 1366472-44-7 C₁₅H₁₈ClN₅ 

Relevant academic research and scientific papers

IMIDAZO [1, 2-C] PYRIMIDIN-2-YLMETHYLPIPERIDINES AS OREXIN RECEPTOR ANTAGONISTS

This invention relates to imidazo[1,2-c]pyrimidin-2-ylmethyl substituted piperidine derivatives and their use as pharmaceuticals.

SUBSTITUTED NITROGEN-CONTAINING SIX-MEMBERED AMINO-HETEROCYCLES AS VANILLOID-1 RECEPTOR ANTAGONISTS FOR TREATING PAIN

The present invention provides a compound of formula (I): Y-J-NH-Z wherein: Y is a quinoline or isoquinoline optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; J is pyridine, pyridazine, pyrazine, pyrimidine or triazine optionally substituted with one or two substituents independently chosen from hydroxy, halogen, haloC1-4alkyl, C1-4alkyl, C3-5cycloalkyl, C1-4alkoxy, hydroxyC1-4alkyl, cyano, hydroxy, C1-4cycloalkoxy, C1-4alkylthio, haloC1-4alkoxy, nitro, Q, (CH2)pQ, NR2R3, -(CH2)pNR2R3 and -O(CH2)pNR2R3; wherein J is substituted at positions meta to each other by NH and Y; and Z is phenyl or pyridyl optionally substituted with one or two substituents independently selected from halogen, haloC1-4alkyl, C1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, nitro and amino; Q is phenyl, a five-membered heterocyclic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, or a six-membered heterocyclic ring containing one, two or three nitrogen atoms, optionally substituted by C1-4alkyl; each R2 and R3 is chosen from H and C1-4alkyl, or R2 and R3, together with the nitrogen atom to which they are attached, may form a six-membered ring optionally containing an oxygen atom or a further nitrogen atom, which ring is optionally substituted by C1-4alkyl or Q; p is 1, 2 or 3; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in methods of therapy; use of it for manufacturing medicaments; and methods of using it to treat diseases requiring administration of a VR1 antagonist such as pain, cough, GERD and depression.